Yongkang Zhang1, Phyllis Johnson1, Philip J Jeng1, M Carrington Reid2, Lisa R Witkin3,4, Bruce R Schackman1,2,5, Jessica S Ancker1, Yuhua Bao6,7. 1. Department of Healthcare Policy & Research, Weill Cornell Medical College, New York, NY, USA. 2. Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 3. Department of Anesthesiology, Weill Cornell Medical College, New York, NY, USA. 4. Division of Pain Medicine, New York-Presbyterian/Lower Manhattan Hospital, New York, NY, USA. 5. Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA. 6. Department of Healthcare Policy & Research, Weill Cornell Medical College, New York, NY, USA. yub2003@med.cornell.edu. 7. Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA. yub2003@med.cornell.edu.
Abstract
BACKGROUND: National guidelines make recommendations regarding the initial opioid prescriptions, but most of the supporting evidence is from the initial episode of care, not the first prescription. OBJECTIVE: To examine associations between features of the first opioid prescription and high-risk opioid use in the 18 months following the first prescription. DESIGN: Retrospective cohort study using data from a large commercial insurance claims database for 2011-2014 to identify individuals with no recent use of opioids and follow them for 18 months after the first opioid prescription. PARTICIPANTS: Privately insured patients aged 18-64 and Medicare Advantage patients aged 65 or older who filled a first opioid prescription between 07/01/2011 and 06/30/2013. MAIN OUTCOMES AND MEASURES: High-risk opioid use was measured by having (1) opioid prescriptions overlapping for 7 days or more, (2) opioid and benzodiazepine prescriptions overlapping for 7 days or more, (3) three or more prescribers of opioids, and (4) a daily dosage exceeding 120 morphine milligram equivalents, in each of the six quarters following the first prescription. KEY RESULTS: All three features of the first prescription were strongly associated with high-risk use. For example, among privately insured patients, receiving a long- (vs. short-) acting first opioid was associated with a 16.9-percentage-point increase (95% CI, 14.3-19.5), a daily MME of 50 or more (vs. less than 30) was associated with a 12.5-percentage-point increase (95% CI, 12.1-12.9), and a supply exceeding 7 days (vs. 3 or fewer days) was associated with a 4.8-percentage-point increase (95% CI, 4.5-5.2), in the probability of having a daily dosage of 120 MMEs or more in the long term, compared to a sample mean of 4.2%. Results for the Medicare Advantage patients were similar. CONCLUSIONS: Long-acting formulation, high daily dosage, and longer duration of the first opioid prescription were each associated with increased high-risk use of opioids in the long term.
BACKGROUND: National guidelines make recommendations regarding the initial opioid prescriptions, but most of the supporting evidence is from the initial episode of care, not the first prescription. OBJECTIVE: To examine associations between features of the first opioid prescription and high-risk opioid use in the 18 months following the first prescription. DESIGN: Retrospective cohort study using data from a large commercial insurance claims database for 2011-2014 to identify individuals with no recent use of opioids and follow them for 18 months after the first opioid prescription. PARTICIPANTS: Privately insured patients aged 18-64 and Medicare Advantage patients aged 65 or older who filled a first opioid prescription between 07/01/2011 and 06/30/2013. MAIN OUTCOMES AND MEASURES: High-risk opioid use was measured by having (1) opioid prescriptions overlapping for 7 days or more, (2) opioid and benzodiazepine prescriptions overlapping for 7 days or more, (3) three or more prescribers of opioids, and (4) a daily dosage exceeding 120 morphine milligram equivalents, in each of the six quarters following the first prescription. KEY RESULTS: All three features of the first prescription were strongly associated with high-risk use. For example, among privately insured patients, receiving a long- (vs. short-) acting first opioid was associated with a 16.9-percentage-point increase (95% CI, 14.3-19.5), a daily MME of 50 or more (vs. less than 30) was associated with a 12.5-percentage-point increase (95% CI, 12.1-12.9), and a supply exceeding 7 days (vs. 3 or fewer days) was associated with a 4.8-percentage-point increase (95% CI, 4.5-5.2), in the probability of having a daily dosage of 120 MMEs or more in the long term, compared to a sample mean of 4.2%. Results for the Medicare Advantage patients were similar. CONCLUSIONS: Long-acting formulation, high daily dosage, and longer duration of the first opioid prescription were each associated with increased high-risk use of opioids in the long term.
Entities:
Keywords:
health services research; pain; physician behavior; prescription drug abuse
Authors: Roger Chou; Judith A Turner; Emily B Devine; Ryan N Hansen; Sean D Sullivan; Ian Blazina; Tracy Dana; Christina Bougatsos; Richard A Deyo Journal: Ann Intern Med Date: 2015-02-17 Impact factor: 25.391
Authors: Matthew Miller; Catherine W Barber; Sarah Leatherman; Jennifer Fonda; John A Hermos; Kelly Cho; David R Gagnon Journal: JAMA Intern Med Date: 2015-04 Impact factor: 21.873
Authors: Daniella Meeker; Jeffrey A Linder; Craig R Fox; Mark W Friedberg; Stephen D Persell; Noah J Goldstein; Tara K Knight; Joel W Hay; Jason N Doctor Journal: JAMA Date: 2016-02-09 Impact factor: 56.272
Authors: Jane A Gwira Baumblatt; Caleb Wiedeman; John R Dunn; William Schaffner; Leonard J Paulozzi; Timothy F Jones Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Ellen Meara; Jill R Horwitz; Wilson Powell; Lynn McClelland; Weiping Zhou; A James O'Malley; Nancy E Morden Journal: N Engl J Med Date: 2016-06-22 Impact factor: 91.245
Authors: Lia D Delaney; Vidhya Gunaseelan; Heidi Rieck; James Michael Dupree; Brian R Hallstrom; Jennifer F Waljee Journal: J Arthroplasty Date: 2020-04-14 Impact factor: 4.757
Authors: Kevin Berardino; Austin H Carroll; Daniel Popovsky; Robert Ricotti; Matthew D Civilette; William F Sherman; Alan D Kaye Journal: Orthop Rev (Pavia) Date: 2022-05-31
Authors: Stephen G Henry; Susan L Stewart; Eryn Murphy; Iraklis Erik Tseregounis; Andrew J Crawford; Aaron B Shev; James J Gasper; Daniel J Tancredi; Magdalena Cerdá; Brandon D L Marshall; Garen J Wintemute Journal: J Gen Intern Med Date: 2021-03-19 Impact factor: 5.128
Authors: Yuhua Bao; Hao Zhang; Katherine Wen; Phyllis Johnson; Philip J Jeng; Lisa R Witkin; Sean Nicholson; M Carrington Reid; Bruce R Schackman Journal: Am J Prev Med Date: 2021-07-04 Impact factor: 6.604
Authors: Hao Zhang; Srikar Tallavajhala; Shashi N Kapadia; Philip J Jeng; Yuyan Shi; Hefei Wen; Yuhua Bao Journal: Med Care Date: 2020-12 Impact factor: 3.178